drugset
drugset / Trial / NCT00152399

Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding

NCT00152399 ↗

Phase 2 Completed 370 enrolled UCB Pharma
RandomizedParallel-groupDouble-blind

Summary

To assess the efficacy and safety of the early administration of somatostatin in infusion during 72 hours plus 2 boluses, compared to placebo in the control of acute severe UGIB with suspicion of PUB.

Timeline

Start
2000-09
Primary completion
2005-10
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatostatin Traditional medicine (herbal / TCM) 12 mg Intravenous

Indications

peptic ulcer disease